In less than a month, President Donald Trump has signed two major executive orders to overhaul the nation’s prescription drug pricing system. These orders have placed Pharmacy Benefit Managers (PBMs) at the center of the president’s ire and revived a controversial “Most Favored Nation” pricing policy that ties US drug prices to those abroad.